Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology
Disease Category: Schizophrenia and Schizoaffective Disorders
Location: United States, IL
A phase III, multicenter, randomized, 12-week, double-blind, parallel group, placebo controlled study to evaluate the efficacy and safety of R04917838 in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics followed by a 40-week double-blind, parallel-group, placebo controlled treatment period.
This study will be conducted to further investigate whether or not administration of RO4917838 along with a current antipsychotic regimen to patients with poorly controlled symptoms can help to achieve better control across mostly positive schizophrenia symptoms and consequently improve functioning.
Please contact Alexian Brothers for more information on participation.
CW ID: 176875
Date Last Changed:
July 22, 2013
Alexian Brothers Hospital Network1786 Moon Lake Boulevard, Suite 200Hoffman Estates, IL 60169Phone: 847-230-3599
Alexian Brothers Hospital Network
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2015 CenterWatch.